6/12/2013 8:32:38 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Jerusalem, Israel and Lund, Sweden, June 12(th), 2013 - Teva Pharmaceutical
Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI)
announced today the results of a Phase IIa study of oral laquinimod designed to
assess safety, tolerability and clinical efficacy in patients with active lupus
nephritis, one of the most serious manifestations of systemic lupus
erythematosus (SLE or lupus)that can lead to chronic kidney failure(1).
Treatment with laquinimod provided an additive effect in improving renal
function when combined with current standard of care for active lupus nephritis
(mycophenolate mofetil and corticosteroids), compared with standard of care
alone. The data will be presented during the European League Against Rheumatism
(EULAR) Annual European Congress of Rheumatology in Madrid, 12-15 June, 2013 as
part of the late-breaking news session.
Help employers find you! Check out all the jobs and post your resume.
comments powered by